Mechanism-based cancer therapy: resistance to therapy, therapy for resistance (Q38255064)

1 September 2017

1 reference

title

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance (English)

1 reference

1 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25263438%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

P Ramos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25263438%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

29 September 2014

1 reference

1 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25263438%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25263438%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25263438%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

3617-3626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25263438%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2014.314

4 June 2020

exact match

0 references

cites work

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Inferring tumor progression from genomic heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Tamoxifen: catalyst for the change to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Erlotinib in non-small cell lung cancer treatment: current status and future development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

21 January 2018

EGFR-targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Development of PI3K inhibitors: lessons learned from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Mitochondrial regulation by c-Myc and hypoxia-inducible factor-1 alpha controls sensitivity to econazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Targeting the tumor microenvironment: from understanding pathways to effective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Influence of tumour micro-environment heterogeneity on therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Environment-mediated drug resistance: a major contributor to minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Integrin agonists as adjuvants in chemotherapy for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Genetic variegation of clonal architecture and propagating cells in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Intratumor heterogeneity: evolution through space and time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Whole genome sequencing of matched primary and metastatic acral melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Tumour heterogeneity in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Tumor heterogeneity in the clinic: is it a real problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

A new model of patient tumor-derived breast cancer xenografts for preclinical assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Molecular-targeted agents combination therapy for cancer: developments and potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Selection and adaptation during metastatic cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The landscape of cancer genes and mutational processes in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The evolving war on cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

A blueprint for advancing genetics-based cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Cotargeting survival signaling pathways in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.314

Antiestrogenic and antitumor properties of tamoxifen in laboratory animals

31 March 2020

1 reference

12 December 2020

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).

1 reference

12 December 2020

Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

1 reference

12 December 2020

Cotargeting survival signaling pathways in cancer

1 reference

12 December 2020